Open data. by Larissa Brazolotto Ferreira (17671168)

“…</p><p>Results</p><p>There was a significant decrease in BMD in the lumbar spine (1.107 ± 0.109 and 1.075 ± 0.112 g/cm²; <i><i>p</i></i> < 0.001), total body (1.135 ± 0.086 and 1.119 ± 0.085 g/cm²; <i><i>p</i></i> < 0.001), and total proximal femur over the six months of EBF compared to the values obtained from the same EBF group at 15 days postpartum (mean percentage decreases in BMD of −3.4 ± 3.7% (<i><i>p</i></i> < 0.001) in lumbar spine, −2.5 ± 3.4% (<i><i>p</i></i> < 0.001) in total proximal femur, and −1.7 ± 1.9% (<i><i>p</i></i> = 0.001) in total body). …”

Ecological zones of Peru, ranging from the coastal lowlands (Chala) to the high-altitude mountains (Janca) [10]. by Sarah J. Noe (19846136)

Pseudocode of the simulation program (see Supplementary Materials for <i>R</i> codes S1 File). by Farrokh Habibzadeh (12256529)

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

Table 2_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Table 1_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Table 3_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

DIP grouping and aggregation system. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

DIP coding logic example. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

DIP pre-payment and provider behavior mechanism. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

S1 Raw images - by Yoon Seok Nam (20678482)

“…The TSA-treated group exhibited a reduction in the levels of oxidative stress markers 4-Hydroxynonenal and 3-Nitrotyrosine, along with a decrease in inflammatory cytokines, in both the mouse cochlea and in vitro HEI-OC1 (House Ear Institute-Organ of Corti 1) cell and HEK (Human Embryonic Kidney)293T cells. …”

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Nitrogen isotopes. by Sarah J. Noe (19846136)